{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:08:08Z","timestamp":1792843688701,"version":"4.5.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s13304-024-01845-z","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T14:01:46Z","timestamp":1715090506000},"page":"725-741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunosuppression in liver transplant oncology: position paper of the Italian Board of Experts in Liver Transplantation (I-BELT)"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2310-0245","authenticated-orcid":false,"given":"Umberto","family":"Cillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6449-4597","authenticated-orcid":false,"given":"Amedeo","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2491-7625","authenticated-orcid":false,"given":"Alfonso W.","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1715-3794","authenticated-orcid":false,"given":"Matteo","family":"Cescon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6718-8760","authenticated-orcid":false,"given":"Fabrizio","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Giannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8326-069X","authenticated-orcid":false,"given":"Paolo","family":"Magistri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0500-9461","authenticated-orcid":false,"given":"Marco","family":"Vivarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1569-7918","authenticated-orcid":false,"given":"Jacopo","family":"Lanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Italian Board of Experts in Liver Transplantation (I-BELT)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Agnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Andorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Caccamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Colledan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"De Carlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Maria","family":"Ettorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Gruttadauria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mazzaferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tandoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tisone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Vennarecci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"1845_CR1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1053\/j.gastro.2017.09.025","volume":"154","author":"V Mazzaferro","year":"2018","unstructured":"Mazzaferro V, Sposito C, Zhou J et al (2018) Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 154:128\u2013139","journal-title":"Gastroenterology"},{"key":"1845_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1002\/lt.21484","volume":"14","author":"C Toso","year":"2008","unstructured":"Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, Grant DR, Greig PD, Shapiro AMJ, Kneteman NM (2008) Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 14:1107\u20131115","journal-title":"Liver Transpl"},{"key":"1845_CR3","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1053\/j.gastro.2012.05.052","volume":"143","author":"C Duvoux","year":"2012","unstructured":"Duvoux C, Roudot-Thoraval F, Decaens T et al (2012) Liver transplantation for hepatocellular carcinoma: a model including \u03b1-fetoprotein improves the performance of Milan criteria. Gastroenterology 143:986-994.e3","journal-title":"Gastroenterology"},{"key":"1845_CR4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","volume":"33","author":"FY Yao","year":"2001","unstructured":"Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394\u20131403","journal-title":"Hepatology"},{"key":"1845_CR5","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/lt.21445","volume":"14","author":"S-G Lee","year":"2008","unstructured":"Lee S-G, Hwang S, Moon D-B, Ahn C-S, Kim K-H, Sung K-B, Ko G-Y, Park K-M, Ha T-Y, Song G-W (2008) Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 14:935\u2013945","journal-title":"Liver Transpl"},{"key":"1845_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jhep.2007.07.004","volume":"47","author":"V Mazzaferro","year":"2007","unstructured":"Mazzaferro V, Pulvirenti A, Coppa J (2007) Neuroendocrine tumors metastatic to the liver: How to select patients for liver transplantation? J Hepatol 47:460\u2013466","journal-title":"J Hepatol"},{"key":"1845_CR7","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1111\/ajt.13831","volume":"16","author":"V Mazzaferro","year":"2016","unstructured":"Mazzaferro V, Sposito C, Coppa J et al (2016) The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors. Am J Transplant 16:2892\u20132902","journal-title":"Am J Transplant"},{"key":"1845_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1053\/lv.2000.6143","volume":"6","author":"I De Vreede","year":"2000","unstructured":"De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ (2000) Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 6:309\u2013316","journal-title":"Liver Transpl"},{"key":"1845_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1055\/s-2004-828896","volume":"24","author":"JK Heimbach","year":"2004","unstructured":"Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB (2004) Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 24:201\u2013207","journal-title":"Semin Liver Dis"},{"key":"1845_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","volume":"3","author":"KE Lunsford","year":"2018","unstructured":"Lunsford KE, Javle M, Heyne K et al (2018) Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol 3:337\u2013348","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1845_CR11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/SLA.0b013e3182823957","volume":"257","author":"M Hagness","year":"2013","unstructured":"Hagness M, Foss A, Line P-D et al (2013) Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 257:800\u2013806","journal-title":"Ann Surg"},{"key":"1845_CR12","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1097\/SLA.0000000000001165","volume":"262","author":"PD Line","year":"2015","unstructured":"Line PD, Hagness M, Berstad AE, Foss A, Dueland S (2015) A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept. Ann Surg 262:e5\u2013e9","journal-title":"Ann Surg"},{"key":"1845_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/SLA.0000000000003404","volume":"271","author":"S Dueland","year":"2020","unstructured":"Dueland S, Syversveen T, Solheim JM, Solberg S, Grut H, Bj\u00f8rnbeth BA, Hagness M, Line P-D (2020) Survival following liver transplantation for patients with nonresectable liver-only colorectal metastases. Ann Surg 271:212\u2013218","journal-title":"Ann Surg"},{"key":"1845_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/bjs5.50278","volume":"4","author":"TM Smedman","year":"2020","unstructured":"Smedman TM, Line P-D, Hagness M, Syversveen T, Grut H, Dueland S (2020) Liver transplantation for unresectable colorectal liver metastases in patients and donors with extended criteria (SECA-II arm D study). BJS Open 4:467\u2013477","journal-title":"BJS Open"},{"key":"1845_CR15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ejca.2005.02.004","volume":"41","author":"P Czauderna","year":"2005","unstructured":"Czauderna P, Otte JB, Aronson DC, Gauthier F, Mackinlay G, Roebuck D, Plaschkes J, Perilongo G, Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL) (2005) Guidelines for surgical treatment of hepatoblastoma in the modern era\u2013recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 41:1031\u20131036","journal-title":"Eur J Cancer"},{"key":"1845_CR16","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s00247-018-4078-z","volume":"48","author":"AJ Towbin","year":"2018","unstructured":"Towbin AJ, Meyers RL, Woodley H, Miyazaki O, Weldon CB, Morland B, Hiyama E, Czauderna P, Roebuck DJ, Tiao GM (2018) 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol 48:536\u2013554","journal-title":"Pediatr Radiol"},{"key":"1845_CR17","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/00042737-200411000-00025","volume":"16","author":"AS Serralta","year":"2004","unstructured":"Serralta AS, Sanjuan FR, Moya AH, Orbis FC, L\u00f3pez-And\u00fajar R, Pareja EI, Vila JC, Ray\u00f3n M, Juan MB, Mir JP (2004) Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours. Eur J Gastroenterol Hepatol 16:1237\u20131239","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1845_CR18","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/lt.25769","volume":"26","author":"C Ben\u00edtez","year":"2020","unstructured":"Ben\u00edtez C, Inzunza M, Riveros S et al (2020) Living donor liver transplantation for imatinib-resistant gastrointestinal stromal tumor liver metastases: a new therapeutic option in transplant oncology. Liver Transpl 26:945\u2013948","journal-title":"Liver Transpl"},{"key":"1845_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/01.TP.0000164141.34293.6B","volume":"80","author":"S Cameron","year":"2005","unstructured":"Cameron S, Ramadori G, F\u00fczesi L, Sattler B, Gunawan B, M\u00fcller D, Ringe B, Lorf T (2005) Successful liver transplantation in two cases of metastatic gastrointestinal stromal tumors. Transplantation 80:283\u2013284","journal-title":"Transplantation"},{"key":"1845_CR20","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1111\/ajt.15377","volume":"19","author":"S Iesari","year":"2019","unstructured":"Iesari S, Mocchegiani F, Nicolini D, Benedetti Cacciaguerra A, Coletta M, Montalti R, Mandolesi A, Lerut J, Vivarelli M (2019) Liver transplantation for metastatic wild-type gastrointestinal stromal tumor in the era of molecular targeted therapies: report of a first case. Am J Transplant 19:2939\u20132943","journal-title":"Am J Transplant"},{"key":"1845_CR21","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1007\/s12072-020-10091-5","volume":"14","author":"U Cillo","year":"2020","unstructured":"Cillo U, De Carlis L, Del Gaudio M, De Simone P, Fagiuoli S, Lupo F, Tisone G, Volpes R (2020) Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group. Hepatol Int 14:930\u2013943","journal-title":"Hepatol Int"},{"key":"1845_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/TP.0000000000001438","volume":"101","author":"P De Simone","year":"2017","unstructured":"De Simone P, Fagiuoli S, Cescon M, De Carlis L, Tisone G, Volpes R, Cillo U, Consensus Panel (2017) Use of everolimus in liver transplantation: recommendations from a working group. Transplantation 101:239\u2013251","journal-title":"Transplantation"},{"key":"1845_CR23","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1136\/bmj.39504.506319.80","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, Jaeschke R, Helfand M, Liberati A, Vist GE, Sch\u00fcnemann HJ (2008) GRADE: incorporating considerations of resources use into grading recommendations. BMJ 336:1170\u20131173","journal-title":"BMJ"},{"key":"1845_CR24","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","volume":"336","author":"HJ Sch\u00fcnemann","year":"2008","unstructured":"Sch\u00fcnemann HJ, Sch\u00fcnemann AHJ, Oxman AD et al (2008) Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336:1106\u20131110","journal-title":"BMJ"},{"key":"1845_CR25","first-page":"257","volume":"9","author":"GH Guyatt","year":"2009","unstructured":"Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schiinemann HJ (2009) GRADE: going from evidence to recommendations. Chin J Evid Based Med 9:257\u2013259","journal-title":"Chin J Evid Based Med"},{"key":"1845_CR26","first-page":"133","volume":"9","author":"GH Guyatt","year":"2009","unstructured":"Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ (2009) GRADE: What is \u201cquality of evidence\u201d and why is it important to clinicians? Chin J Evid Based Med 9:133\u2013137","journal-title":"Chin J Evid Based Med"},{"key":"1845_CR27","first-page":"8","volume":"9","author":"GH Guyatt","year":"2009","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ (2009) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Chin J Evid Based Med 9:8\u201311","journal-title":"Chin J Evid Based Med"},{"key":"1845_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/hep.27787","volume":"62","author":"C Toso","year":"2015","unstructured":"Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM (2015) Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology 62:158\u2013165","journal-title":"Hepatology"},{"key":"1845_CR29","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s13304-021-01078-4","volume":"73","author":"J Lerut","year":"2021","unstructured":"Lerut J, Foguenne M, Lai Q (2021) Hepatocellular cancer selection systems and liver transplantation: from the tower of babel to an ideal comprehensive score. Updates Surg 73:1599\u20131614","journal-title":"Updates Surg"},{"key":"1845_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6651397","author":"X Zhang","year":"2021","unstructured":"Zhang X, Wu Z, Peng Y, Li D, Jiang Y, Pan F, Li Y, Lai Y, Cui Z, Zhang K (2021) Correlationship between Ki67, VEGF, and p53 and hepatocellular carcinoma recurrence in liver transplant patients. Biomed Res Int. https:\/\/doi.org\/10.1155\/2021\/6651397","journal-title":"Biomed Res Int"},{"key":"1845_CR31","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.transproceed.2022.04.027","volume":"54","author":"B Rovgaliyev","year":"2022","unstructured":"Rovgaliyev B, Tan MY, Lee K-W et al (2022) Sirolimus attenuates calcineurin inhibitor-induced epithelial-mesenchymal transition in hepatocellular carcinoma. Transplant Proc 54:2025\u20132034","journal-title":"Transplant Proc"},{"key":"1845_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20020336","volume":"20","author":"M Guerrero","year":"2019","unstructured":"Guerrero M, Ferr\u00edn G, Rodr\u00edguez-Per\u00e1lvarez M et al (2019) mTOR expression in liver transplant candidates with hepatocellular carcinoma: Impact on histological features and tumour recurrence. Int J Mol Sci 20:1\u201315","journal-title":"Int J Mol Sci"},{"key":"1845_CR33","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/SLA.0000000000004280","volume":"272","author":"AA Schnitzbauer","year":"2020","unstructured":"Schnitzbauer AA, Filmann N, Adam R et al (2020) mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors. Ann Surg 272:855\u2013862","journal-title":"Ann Surg"},{"key":"1845_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.21037\/atm.2020.01.10","volume":"8","author":"S Ling","year":"2020","unstructured":"Ling S, Feng T, Zhan Q et al (2020) Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria. Ann Transl Med 8:80","journal-title":"Ann Transl Med"},{"key":"1845_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-190","author":"AA Schnitzbauer","year":"2010","unstructured":"Schnitzbauer AA, Zuelke C, Graeb C et al (2010) A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer. https:\/\/doi.org\/10.1186\/1471-2407-10-190","journal-title":"BMC Cancer"},{"key":"1845_CR36","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/TP.0000000000000965","volume":"100","author":"EK Geissler","year":"2016","unstructured":"Geissler EK, Schnitzbauer AA, Z\u00f6lke C et al (2016) Sirolimus use in liver transplant recipients with Hepatocellular carcinoma: a randomized, Multicenter, open-label phase 3 trial. Transplantation 100:116\u2013125","journal-title":"Transplantation"},{"key":"1845_CR37","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1111\/apt.15253","volume":"49","author":"SE Grigg","year":"2019","unstructured":"Grigg SE, Sarri GL, Gow PJ, Yeomans ND (2019) Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 49:1260\u20131273","journal-title":"Aliment Pharmacol Ther"},{"key":"1845_CR38","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.937988","volume":"27","author":"G Sapisochin","year":"2022","unstructured":"Sapisochin G, Lee WC, Joo DJ et al (2022) Long-term effects of everolimus-facilitated tacrolimus reduction in living-donor liver transplant recipients with hepatocellular carcinoma. Ann Transplant 27:e937988","journal-title":"Ann Transplant"},{"key":"1845_CR39","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1111\/liv.15396","volume":"42","author":"F Saliba","year":"2022","unstructured":"Saliba F, Duvoux C, Dharancy S et al (2022) Five-year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: results from the CERTITUDE study. Liver Int 42:2513\u20132523","journal-title":"Liver Int"},{"key":"1845_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14823","volume":"36","author":"G Zhang","year":"2022","unstructured":"Zhang G, Duan B, Li G (2022) mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: a systematic review and meta-analysis. Clin Transplant 36:e14823","journal-title":"Clin Transplant"},{"key":"1845_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.hbpd.2022.11.010","volume":"22","author":"P Liu","year":"2023","unstructured":"Liu P, Wang X, Liu H, Wang S-X, Xu Q-G, Wang L, Xu X, Cai J-Z (2023) Sirolimus improves the prognosis of liver recipients with hepatocellular carcinoma: a single-center experience. Hepatobiliary Pancreat Dis Int 22:34\u201340","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"1845_CR42","first-page":"1","volume":"11","author":"HTJ Mantel","year":"2016","unstructured":"Mantel HTJ, Westerkamp AC, Adam R et al (2016) Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival. PLoS\u00a0One 11:1\u201312","journal-title":"PLoS\u00a0One"},{"key":"1845_CR43","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/TP.0000000000003212","volume":"104","author":"G Sapisochin","year":"2020","unstructured":"Sapisochin G, Javle M, Lerut J, Ohtsuka M, Ghobrial M, Hibi T, Kwan NM, Heimbach J (2020) Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ILTS transplant oncology consensus conference. Transplantation 104:1125\u20131130","journal-title":"Transplantation"},{"key":"1845_CR44","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1245\/s10434-020-08682-5","volume":"27","author":"T Kitajima","year":"2020","unstructured":"Kitajima T, Hibi T, Moonka D, Sapisochin G, Abouljoud MS, Nagai S (2020) Center experience affects liver transplant outcomes in patients with hilar cholangiocarcinoma. Ann Surg Oncol 27:5209\u20135221","journal-title":"Ann Surg Oncol"},{"key":"1845_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","volume":"143","author":"S Darwish Murad","year":"2012","unstructured":"Darwish Murad S, Kim WR, Harnois DM et al (2012) Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143:88\u201398 (e3; quiz e14)","journal-title":"Gastroenterology"},{"key":"1845_CR46","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","volume":"72","author":"V Mazzaferro","year":"2020","unstructured":"Mazzaferro V, Gorgen A, Roayaie S, Droz dit Busset M, Sapisochin G (2020) Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol 72:364\u2013377","journal-title":"J Hepatol"},{"key":"1845_CR47","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s13304-021-01064-w","volume":"73","author":"S Gruttadauria","year":"2021","unstructured":"Gruttadauria S, Barbara M, Liotta R (2021) Liver transplantation for unresectable intrahepatic cholangiocarcinoma: an Italian experience. Updates Surg 73:1587\u20131588","journal-title":"Updates Surg"},{"key":"1845_CR48","doi-asserted-by":"publisher","first-page":"363","DOI":"10.6002\/ect.2018.0024","volume":"17","author":"F Dondorf","year":"2019","unstructured":"Dondorf F, Ute\u00df F, Fahrner R, Felgendreff P, Ardelt M, Tautenhahn H-M, Settmacher U, Rauchfu\u00df F (2019) Liver Transplant for Perihilar Cholangiocarcinoma (Klatskin Tumor): the essential role of patient selection. Exp Clin Transplant 17:363\u2013369","journal-title":"Exp Clin Transplant"},{"key":"1845_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17050735","author":"S Granata","year":"2016","unstructured":"Granata S, Dalla Gassa A, Carraro A, Brunelli M, Stallone G, Lupo A, Zaza G (2016) Sirolimus and everolimus pathway: reviewing candidate genes influencing their intracellular effects. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms17050735","journal-title":"Int J Mol Sci"},{"key":"1845_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2360-8","volume":"16","author":"N Heits","year":"2016","unstructured":"Heits N, Heinze T, Bernsmeier A, Kerber J, Hauser C, Becker T, Kalthoff H, Egberts JH, Braun F (2016) Influence of mTOR-inhibitors and mycophenolic acid on human cholangiocellular carcinoma and cancer associated fibroblasts. BMC Cancer 16:1\u201312","journal-title":"BMC Cancer"},{"key":"1845_CR51","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2147\/OTT.S297643","volume":"14","author":"W Yang","year":"2021","unstructured":"Yang W, Sun Y (2021) Promising molecular targets for the targeted therapy of biliary tract cancers: an overview. Onco Targets Ther 14:1341\u20131366","journal-title":"Onco Targets Ther"},{"key":"1845_CR52","first-page":"1","volume":"20","author":"CE Wu","year":"2019","unstructured":"Wu CE, Chen MH, Yeh CN (2019) mTOR inhibitors in advanced biliary tract cancers. Int J Mol Sci 20:1\u201316","journal-title":"Int J Mol Sci"},{"key":"1845_CR53","doi-asserted-by":"publisher","first-page":"17220","DOI":"10.18632\/oncotarget.7948","volume":"7","author":"H Peng","year":"2016","unstructured":"Peng H, Zhang Q, Li J et al (2016) Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget 7:17220\u201317229","journal-title":"Oncotarget"},{"key":"1845_CR54","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.18632\/oncotarget.1706","volume":"5","author":"M-H Chen","year":"2014","unstructured":"Chen M-H, Chiang K-C, Cheng C-T et al (2014) Antitumor activity of the combination of an HSP90 inhibitor and a PI3K\/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget 5:2372\u20132389","journal-title":"Oncotarget"},{"key":"1845_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142124","volume":"10","author":"A Fraveto","year":"2015","unstructured":"Fraveto A, Cardinale V, Bragazzi MC et al (2015) Sensitivity of human intrahepatic cholangiocarcinoma subtypes to chemotherapeutics and molecular targeted agents: a study on primary cell cultures. PLoS\u00a0One 10:e0142124","journal-title":"PLoS\u00a0One"},{"key":"1845_CR56","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41416-018-0021-1","volume":"118","author":"DK Lau","year":"2018","unstructured":"Lau DK, Tay RY, Yeung YH, Chionh F, Mooi J, Murone C, Skrinos E, Price TJ, Mariadason JM, Tebbutt NC (2018) Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol study. Br J Cancer 118:966\u2013971","journal-title":"Br J Cancer"},{"key":"1845_CR57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10147-007-0733-3","volume":"13","author":"M Rizell","year":"2008","unstructured":"Rizell M, Andersson M, Cahlin C, Hafstr\u00f6m L, Olausson M, Lindn\u00e9r P (2008) Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 13:66\u201370","journal-title":"Int J Clin Oncol"},{"key":"1845_CR58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3892\/mco.2017.1272","volume":"7","author":"KS Jung","year":"2017","unstructured":"Jung KS, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST (2017) Pilot study of sirolimus in patients with PIK3CA mutant\/amplified refractory solid cancer. Mol Clin Oncol 7:27\u201331","journal-title":"Mol Clin Oncol"},{"key":"1845_CR59","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s10637-014-0096-3","volume":"32","author":"BA Costello","year":"2014","unstructured":"Costello BA, Borad MJ, Qi Y, Kim GP, Northfelt DW, Erlichman C, Alberts SR (2014) Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Invest New Drugs 32:710\u2013716","journal-title":"Invest New Drugs"},{"key":"1845_CR60","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1097\/TP.0000000000003118","volume":"104","author":"T Hibi","year":"2020","unstructured":"Hibi T, Rela M, Eason JD, Line P-D, Fung J, Sakamoto S, Selzner N, Man K, Ghobrial RM, Sapisochin G (2020) Liver transplantation for colorectal and neuroendocrine liver metastases and hepatoblastoma. Working group report from the ILTS transplant oncology consensus conference. Transplantation 104:1131\u20131135","journal-title":"Transplantation"},{"key":"1845_CR61","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019\u2019Toole D, Costa F et al (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103:172\u2013185","journal-title":"Neuroendocrinology"},{"key":"1845_CR62","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. The Lancet 387:968\u2013977","journal-title":"The Lancet"},{"key":"1845_CR63","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/14656566.2018.1476492","volume":"19","author":"L Lee","year":"2018","unstructured":"Lee L, Ito T, Jensen RT (2018) Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 19:909\u2013928","journal-title":"Expert Opin Pharmacother"},{"key":"1845_CR64","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.pan.2020.07.010","volume":"20","author":"R Shimoyama","year":"2020","unstructured":"Shimoyama R, Hijioka S, Mizuno N et al (2020) Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical On. Pancreatology 20:1183\u20131188","journal-title":"Pancreatology"},{"key":"1845_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12113115","volume":"12","author":"E Rampazzo","year":"2020","unstructured":"Rampazzo E, Cecchin E, Del Bianco P et al (2020) Genetic variants of the TERT gene, telomere length, and circulating tert as prognostic markers in rectal cancer patients. Cancers (Basel) 12:1\u201315","journal-title":"Cancers (Basel)"},{"key":"1845_CR66","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/bjc.2017.492","volume":"118","author":"E Rampazzo","year":"2018","unstructured":"Rampazzo E, Del Bianco P, Bertorelle R et al (2018) The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients. Br J Cancer 118:878\u2013886","journal-title":"Br J Cancer"},{"key":"1845_CR67","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/sj.bjc.6605644","volume":"102","author":"E Rampazzo","year":"2010","unstructured":"Rampazzo E, Bertorelle R, Serra L, Terrin L, Candiotto C, Pucciarelli S, Del BP, Nitti D, De Rossi A (2010) Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers. Br J Cancer 102:1300\u20131305","journal-title":"Br J Cancer"},{"key":"1845_CR68","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.1158\/1078-0432.CCR-08-0478","volume":"14","author":"L Terrin","year":"2008","unstructured":"Terrin L, Rampazzo E, Pucciarelli S, Agostini M, Bertorelle R, Esposito G, DelBianco P, Nitti D, De Rossi A (2008) Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: Implications for monitoring of neoplastic disease. Clin Cancer Res 14:7444\u20137451","journal-title":"Clin Cancer Res"},{"key":"1845_CR69","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/bjs.10651","volume":"105","author":"H Grut","year":"2018","unstructured":"Grut H, Solberg S, Seierstad T, Revheim ME, Egge TS, Larsen SG, Line PD, Dueland S (2018) Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. Br J Surg 105:295\u2013301","journal-title":"Br J Surg"},{"key":"1845_CR70","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S1470-2045(16)30598-8","volume":"18","author":"RL Meyers","year":"2017","unstructured":"Meyers RL, Maibach R, Hiyama E et al (2017) Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children\u2019s Hepatic tumors International Collaboration. Lancet Oncol 18:122\u2013131","journal-title":"Lancet Oncol"},{"key":"1845_CR71","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jhep.2020.03.025","volume":"73","author":"J Carrillo-Reixach","year":"2020","unstructured":"Carrillo-Reixach J, Torrens L, Simon-Coma M et al (2020) Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. J Hepatol 73:328\u2013341","journal-title":"J Hepatol"},{"key":"1845_CR72","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1016\/j.ejca.2011.12.032","volume":"48","author":"F Wagner","year":"2012","unstructured":"Wagner F, Henningsen B, Lederer C, Eichenm\u00fcller M, G\u00f6deke J, M\u00fcller-H\u00f6cker J, von Schweinitz D, Kappler R (2012) Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients. Eur J Cancer 48:2442\u20132450","journal-title":"Eur J Cancer"},{"key":"1845_CR73","doi-asserted-by":"publisher","first-page":"113S","DOI":"10.1016\/S0041-1345(03)00223-9","volume":"35","author":"R Sindhi","year":"2003","unstructured":"Sindhi R (2003) Sirolimus in pediatric transplant recipients. Transplant Proc 35:113S-114S","journal-title":"Transplant Proc"},{"key":"1845_CR74","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1399-3046.2004.00156.x","volume":"8","author":"C Jim\u00e9nez-Rivera","year":"2004","unstructured":"Jim\u00e9nez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL (2004) Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 8:243\u2013248","journal-title":"Pediatr Transplant"},{"key":"1845_CR75","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/petr.13369","volume":"23","author":"RJ Hendrickson","year":"2019","unstructured":"Hendrickson RJ, Sujka J, Fischer R, Manalang M, Daniel J, Andrews WS (2019) Indications and efficacy of conversion from tacrolimus- to sirolimus-based immunosuppression in pediatric patients who underwent liver transplantation for unresectable hepatoblastoma. Pediatr Transplant 23:2\u20137","journal-title":"Pediatr Transplant"},{"key":"1845_CR76","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/j.jpedsurg.2011.09.003","volume":"46","author":"Y Ueda","year":"2011","unstructured":"Ueda Y, Hiyama E, Kamimatsuse A, Kamei N, Ogura K, Sueda T (2011) Wnt signaling and telomerase activation of hepatoblastoma: correlation with chemosensitivity and surgical resectability. J Pediatr Surg 46:2221\u20132227","journal-title":"J Pediatr Surg"},{"key":"1845_CR77","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ng.3252","volume":"47","author":"K Schulze","year":"2015","unstructured":"Schulze K, Imbeaud S, Letouz\u00e9 E et al (2015) Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47:505\u2013511","journal-title":"Nat Genet"},{"key":"1845_CR78","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrgastro.2016.198","volume":"14","author":"K Pantel","year":"2017","unstructured":"Pantel K, Alix-Panabi\u00e8res C (2017) Circulating tumour cells and cell-free DNA in gastrointestinal cancer. Nat Rev Gastroenterol Hepatol 14:73\u201374","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1845_CR79","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s11684-017-0526-7","volume":"11","author":"J Wang","year":"2017","unstructured":"Wang J, Chang S, Li G, Sun Y (2017) Application of liquid biopsy in precision medicine: opportunities and challenges. Front Med 11:522\u2013527","journal-title":"Front Med"},{"key":"1845_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102972","author":"Y Duan","year":"2020","unstructured":"Duan Y, Haybaeck J, Yang Z (2020) Therapeutic potential of PI3K\/AKT\/mTOR pathway in gastrointestinal stromal tumors: rationale and progress. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12102972","journal-title":"Cancers (Basel)"},{"key":"1845_CR81","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1093\/annonc\/mdq076","volume":"21","author":"P Sch\u00f6ffski","year":"2010","unstructured":"Sch\u00f6ffski P, Reichardt P, Blay J-Y, Dumez H, Morgan JA, Ray-Coquard I, Hollaender N, Jappe A, Demetri GD (2010) A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol 21:1990\u20131998","journal-title":"Ann Oncol"},{"key":"1845_CR82","doi-asserted-by":"publisher","first-page":"604","DOI":"10.5009\/gnl15017","volume":"10","author":"Q Wei","year":"2016","unstructured":"Wei Q, Xu X, Wang C et al (2016) Efficacy and safety of a steroid-free immunosuppressive regimen after liver transplantation for hepatocellular carcinoma. Gut Liver 10:604\u2013610","journal-title":"Gut Liver"},{"key":"1845_CR83","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3350\/cmh.2014.20.2.192","volume":"20","author":"JY Lee","year":"2014","unstructured":"Lee JY, Kim YH, Yi NJ et al (2014) Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Clin Mol Hepatol 20:192\u2013203","journal-title":"Clin Mol Hepatol"},{"key":"1845_CR84","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.hbpd.2019.05.006","volume":"18","author":"Q Lai","year":"2019","unstructured":"Lai Q, Iesari S, Finkenstedt A, Hoppe-Lotichius M, Foguenne M, Lehner K, Otto G, Lerut J (2019) Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment: a multicenter European experience. Hepatobiliary Pancreat Dis Int 18:517\u2013524","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"1845_CR85","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.trre.2018.04.001","volume":"32","author":"U Cillo","year":"2018","unstructured":"Cillo U, Bechstein WO, Berlakovich G, Dutkowski P, Lehner F, Nadalin S, Saliba F, Schlitt HJ, Pratschke J (2018) Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression. Transplant Rev (Orlando) 32:142\u2013150","journal-title":"Transplant Rev (Orlando)"},{"key":"1845_CR86","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/ajt.15697","volume":"20","author":"EC Verna","year":"2020","unstructured":"Verna EC, Patel YA, Aggarwal A et al (2020) Liver transplantation for hepatocellular carcinoma: management after the transplant. Am J Transplant 20:333\u2013347","journal-title":"Am J Transplant"},{"key":"1845_CR87","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.3390\/cancers13194882","volume":"13","author":"F Pelizzaro","year":"2021","unstructured":"Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP (2021) Management of hepatocellular carcinoma recurrence after liver transplantation. Cancers (Basel) 13:4882","journal-title":"Cancers (Basel)"},{"key":"1845_CR88","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.transproceed.2010.02.014","volume":"42","author":"A Valdivieso","year":"2010","unstructured":"Valdivieso A, Bustamante J, Gastaca M et al (2010) Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 42:660\u2013662","journal-title":"Transplant Proc"},{"key":"1845_CR89","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/lt.20128","volume":"10","author":"S Roayaie","year":"2004","unstructured":"Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR, Schwartz ME (2004) Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 10:534\u2013540","journal-title":"Liver Transpl"},{"key":"1845_CR90","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1245\/s10434-014-4273-6","volume":"22","author":"G Sapisochin","year":"2015","unstructured":"Sapisochin G, Goldaracena N, Astete S et al (2015) Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series. Ann Surg Oncol 22:2286\u20132294","journal-title":"Ann Surg Oncol"},{"key":"1845_CR91","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/lt.24742","volume":"23","author":"E Fernandez-Sevilla","year":"2017","unstructured":"Fernandez-Sevilla E, Allard M-A, Selten J, Golse N, Vibert E, Sa Cunha A, Cherqui D, Castaing D, Adam R (2017) Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection? Liver Transpl 23:440\u2013447","journal-title":"Liver Transpl"},{"key":"1845_CR92","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ejso.2009.10.001","volume":"36","author":"A Kornberg","year":"2010","unstructured":"Kornberg A, K\u00fcpper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, Wilberg J (2010) Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol (EJSO) 36:275\u2013280","journal-title":"Eur J Surg Oncol (EJSO)"},{"key":"1845_CR93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/PL00009947","volume":"5","author":"E Regalia","year":"1998","unstructured":"Regalia E, Fassati LR, Valente U, Pulvirenti A, Damilano I, Dardano G, Montalto F, Coppa J, Mazzaferro V (1998) Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 5:29\u201334","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"1845_CR94","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/SLA.0000000000001894","volume":"266","author":"AS Bodzin","year":"2017","unstructured":"Bodzin AS, Lunsford KE, Markovic D, Harlander-Locke MP, Busuttil RW, Agopian VG (2017) Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics. Ann Surg 266:118\u2013125","journal-title":"Ann Surg"},{"key":"1845_CR95","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.athoracsur.2007.10.065","volume":"85","author":"MJ Bates","year":"2008","unstructured":"Bates MJ, Farkas E, Taylor D, McFadden PM (2008) Pulmonary resection of metastatic hepatocellular carcinoma after liver transplantation. Ann Thorac Surg 85:412\u2013415","journal-title":"Ann Thorac Surg"},{"key":"1845_CR96","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.lungcan.2010.02.014","volume":"70","author":"KN Han","year":"2010","unstructured":"Han KN, Kim YT, Yoon J-H, Suh K-S, Song JY, Kang CH, Sung SW, Kim JH (2010) Role of surgical resection for pulmonary metastasis of hepatocellular carcinoma. Lung Cancer 70:295\u2013300","journal-title":"Lung Cancer"},{"key":"1845_CR97","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1007\/s00268-012-1533-0","volume":"36","author":"S Hwang","year":"2012","unstructured":"Hwang S, Kim Y-H, Kim DK et al (2012) Resection of pulmonary metastases from hepatocellular carcinoma following liver transplantation. World J Surg 36:1592\u20131602","journal-title":"World J Surg"},{"key":"1845_CR98","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jss.2015.07.033","volume":"200","author":"J Huang","year":"2016","unstructured":"Huang J, Yan L, Wu H, Yang J, Liao M, Zeng Y (2016) Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation? J Surg Res 200:122\u2013130","journal-title":"J Surg Res"},{"key":"1845_CR99","doi-asserted-by":"publisher","first-page":"142","DOI":"10.7182\/pit2014632","volume":"24","author":"E Gringeri","year":"2014","unstructured":"Gringeri E, Boetto R, Bassi D, D\u2019Amico FE, Polacco M, Romano M, Neri D, Feltracco P, Zanus G, Cillo U (2014) Laparoscopic microwave thermal ablation for late recurrence of local hepatocellular carcinoma after liver transplant: case report. Prog Transplant 24:142\u2013145","journal-title":"Prog Transplant"},{"key":"1845_CR100","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3109\/02656736.2015.1091953","volume":"31","author":"H Zhai","year":"2015","unstructured":"Zhai H, Liang P, Yu X, Cheng Z, Han Z-Y, Liu F, Yu J (2015) Microwave ablation in treating intrahepatic recurrence of hepatocellular carcinoma after liver transplantation: an analysis of 11 cases. Int J Hyperth 31:863\u2013868","journal-title":"Int J Hyperth"},{"key":"1845_CR101","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3348\/kjr.2007.8.4.320","volume":"8","author":"HK Ko","year":"2007","unstructured":"Ko HK, Ko G-Y, Yoon HK, Sung K-B (2007) Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation. Korean J Radiol 8:320\u2013327","journal-title":"Korean J Radiol"},{"key":"1845_CR102","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jvir.2009.11.006","volume":"21","author":"B Zhou","year":"2010","unstructured":"Zhou B, Shan H, Zhu K-S, Jiang Z-B, Guan S-H, Meng X-C, Zeng X-C (2010) Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. J Vasc Interv Radiol 21:333\u2013338","journal-title":"J Vasc Interv Radiol"},{"key":"1845_CR103","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jhep.2013.02.026","volume":"59","author":"C Sposito","year":"2013","unstructured":"Sposito C, Mariani L, Germini A, Flores Reyes M, Bongini M, Grossi G, Bhoori S, Mazzaferro V (2013) Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol 59:59\u201366","journal-title":"J Hepatol"},{"key":"1845_CR104","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.dld.2015.01.001","volume":"47","author":"A Mancuso","year":"2015","unstructured":"Mancuso A, Mazzola A, Cabibbo G, Perricone G, Enea M, Galvano A, Zavaglia C, Belli L, Camm\u00e0 C (2015) Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis. Dig Liver Dis 47:324\u2013330","journal-title":"Dig Liver Dis"},{"key":"1845_CR105","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jhep.2010.01.025","volume":"52","author":"S Bhoori","year":"2010","unstructured":"Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, Lampis A, Mazzaferro V (2010) Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 52:771\u2013775","journal-title":"J Hepatol"},{"key":"1845_CR106","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.3748\/wjg.v16.i43.5518","volume":"16","author":"Y Wang","year":"2010","unstructured":"Wang Y, Speeg KV, Washburn WK, Halff G (2010) Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report. World J Gastroenterol 16:5518\u20135522","journal-title":"World J Gastroenterol"},{"key":"1845_CR107","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/lt.22434","volume":"18","author":"C Gomez-Martin","year":"2012","unstructured":"Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B (2012) Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 18:45\u201352","journal-title":"Liver Transpl"},{"key":"1845_CR108","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.dld.2011.12.009","volume":"44","author":"A Weinmann","year":"2012","unstructured":"Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, D\u00fcber C, Schuchmann M, Otto G, Galle PR, W\u00f6rns M-A (2012) Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Dig Liver Dis 44:432\u2013437","journal-title":"Dig Liver Dis"},{"key":"1845_CR109","doi-asserted-by":"publisher","first-page":"e14669","DOI":"10.1200\/jco.2010.28.15_suppl.e14669","volume":"28","author":"B Ryoo","year":"2010","unstructured":"Ryoo B, Yoon D, Ryu M, Lee S, Hwang S, Suh D, Lee J, Kim T, Chang H, Kang Y (2010) Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. J Clin Oncol 28:e14669\u2013e14669","journal-title":"J Clin Oncol"},{"key":"1845_CR110","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/TP.0000000000002955","volume":"104","author":"F Invernizzi","year":"2020","unstructured":"Invernizzi F, Iavarone M, Zavaglia C et al (2020) Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation. Transplantation 104:568\u2013574","journal-title":"Transplantation"},{"key":"1845_CR111","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.amjsurg.2016.10.006","volume":"213","author":"RCG Martin","year":"2017","unstructured":"Martin RCG, Bruenderman E, Cohn A et al (2017) Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: observations from a US regional analysis of the GIDEON registry. Am J Surg 213:688\u2013695","journal-title":"Am J Surg"},{"key":"1845_CR112","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1158\/1535-7163.MCT-10-0666","volume":"10","author":"A-C Piguet","year":"2011","unstructured":"Piguet A-C, Saar B, Hlushchuk R, St-Pierre MV, McSheehy PMJ, Radojevic V, Afthinos M, Terracciano L, Djonov V, Dufour J-F (2011) Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Mol Cancer Ther 10:1007\u20131017","journal-title":"Mol Cancer Ther"},{"key":"1845_CR113","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/TP.0b013e3181daac69","volume":"90","author":"U Herden","year":"2010","unstructured":"Herden U, Fischer L, Sch\u00e4fer H, Nashan B, von Baehr V, Sterneck M (2010) Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient. Transplantation 90:98\u201399","journal-title":"Transplantation"},{"key":"1845_CR114","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jhep.2010.08.038","volume":"54","author":"O Waidmann","year":"2011","unstructured":"Waidmann O, Hofmann W-P, Zeuzem S, Trojan J (2011) mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. J Hepatol 54:396\u2013398","journal-title":"J Hepatol"},{"key":"1845_CR115","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.transproceed.2013.10.035","volume":"46","author":"P De Simone","year":"2014","unstructured":"De Simone P, Crocetti L, Pezzati D et al (2014) Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc 46:241\u2013244","journal-title":"Transplant Proc"},{"key":"1845_CR116","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1111\/ajt.15551","volume":"19","author":"M Iavarone","year":"2019","unstructured":"Iavarone M, Invernizzi F, Czauderna C et al (2019) Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. Am J Transplant 19:3176\u20133184","journal-title":"Am J Transplant"},{"key":"1845_CR117","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/lt.26264","volume":"27","author":"M Iavarone","year":"2021","unstructured":"Iavarone M, Invernizzi F, Ivanics T et al (2021) Regorafenib efficacy after sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation: a retrospective study. Liver Transpl 27:1767\u20131778","journal-title":"Liver Transpl"},{"key":"1845_CR118","doi-asserted-by":"publisher","first-page":"11305","DOI":"10.1038\/s41598-017-11810-z","volume":"7","author":"M Ravaioli","year":"2017","unstructured":"Ravaioli M, Cucchetti A, Pinna AD et al (2017) The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation. Sci Rep 7:11305","journal-title":"Sci Rep"},{"key":"1845_CR119","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/CJI.0000000000000180","volume":"40","author":"AS Kittai","year":"2017","unstructured":"Kittai AS, Oldham H, Cetnar J, Taylor M (2017) Immune checkpoint inhibitors in organ transplant patients. J Immunother 40:277\u2013281","journal-title":"J Immunother"},{"key":"1845_CR120","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26682","author":"BD Friend","year":"2017","unstructured":"Friend BD, Venick RS, McDiarmid SV, Zhou X, Naini B, Wang H, Farmer DG, Busuttil RW, Federman N (2017) Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.26682","journal-title":"Pediatr Blood Cancer"},{"key":"1845_CR121","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/annonc\/mdx548","volume":"29","author":"P Biondani","year":"2018","unstructured":"Biondani P, De Martin E, Samuel D (2018) Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient. Ann Oncol 29:286\u2013287","journal-title":"Ann Oncol"},{"key":"1845_CR122","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","volume":"9","author":"TT DeLeon","year":"2018","unstructured":"DeLeon TT, Salomao MA, Aqel BA et al (2018) Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol 9:1054\u20131062","journal-title":"J Gastrointest Oncol"},{"key":"1845_CR123","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000814","volume":"4","author":"D Gassmann","year":"2018","unstructured":"Gassmann D, Weiler S, Mertens JC, Reiner CS, Vrugt B, N\u00e4geli M, Mangana J, M\u00fcllhaupt B, Jenni F, Misselwitz B (2018) Liver allograft failure after nivolumab treatment\u2014a case report with systematic literature research. Transplant Direct 4:e376","journal-title":"Transplant Direct"},{"key":"1845_CR124","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","volume":"32","author":"EJ Lipson","year":"2014","unstructured":"Lipson EJ, Bodell MA, Kraus ES, Sharfman WH (2014) Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. J Clin Oncol 32:e69-71","journal-title":"J Clin Oncol"},{"key":"1845_CR125","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMc1509268","volume":"374","author":"EJ Lipson","year":"2016","unstructured":"Lipson EJ, Bagnasco SM, Moore J, Jang S, Patel MJ, Zachary AA, Pardoll DM, Taube JM, Drake CG (2016) Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med 374:896\u2013898","journal-title":"N Engl J Med"},{"key":"1845_CR126","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1111\/j.1600-6143.2010.03128.x","volume":"10","author":"M Masetti","year":"2010","unstructured":"Masetti M, Montalti R, Rompianesi G, Codeluppi M, Gerring R, Romano A, Begliomini B, Di Benedetto F, Gerunda GE (2010) Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 10:2252\u20132262","journal-title":"Am J Transplant"},{"key":"1845_CR127","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1111\/j.1600-6143.2012.04049.x","volume":"12","author":"L Fischer","year":"2012","unstructured":"Fischer L, Klempnauer J, Beckebaum S et al (2012) A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation\u2013PROTECT. Am J Transplant 12:1855\u20131865","journal-title":"Am J Transplant"},{"key":"1845_CR128","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1111\/j.1600-6143.2012.04212.x","volume":"12","author":"P De Simone","year":"2012","unstructured":"De Simone P, Nevens F, De Carlis L et al (2012) Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 12:3008\u20133020","journal-title":"Am J Transplant"},{"key":"1845_CR129","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/ajt.12280","volume":"13","author":"F Saliba","year":"2013","unstructured":"Saliba F, De Simone P, Nevens F et al (2013) Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 13:1734\u20131745","journal-title":"Am J Transplant"},{"key":"1845_CR130","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/ajt.12615","volume":"14","author":"M Sterneck","year":"2014","unstructured":"Sterneck M, Kaiser GM, Heyne N et al (2014) Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant 14:701\u2013710","journal-title":"Am J Transplant"},{"key":"1845_CR131","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/TP.0000000000000555","volume":"99","author":"L Fischer","year":"2015","unstructured":"Fischer L, Saliba F, Kaiser GM et al (2015) Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study. Transplantation 99:1455\u20131462","journal-title":"Transplantation"},{"key":"1845_CR132","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1111\/ajt.14623","volume":"18","author":"L-B Jeng","year":"2018","unstructured":"Jeng L-B, Lee SG, Soin AS et al (2018) Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant 18:1435\u20131446","journal-title":"Am J Transplant"},{"key":"1845_CR133","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1097\/TP.0000000000003394","volume":"105","author":"S-G Lee","year":"2021","unstructured":"Lee S-G, Jeng L-B, Saliba F et al (2021) Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients: 24-month results from the pooled analysis of 2 randomized controlled trials. Transplantation 105:1564\u20131575","journal-title":"Transplantation"},{"key":"1845_CR134","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/lt.25879","volume":"26","author":"F Saliba","year":"2020","unstructured":"Saliba F, Dharancy S, Salam\u00e9 E et al (2020) Time to conversion to an everolimus-based regimen: renal outcomes in liver transplant recipients from the EVEROLIVER registry. Liver Transpl 26:1465\u20131476","journal-title":"Liver Transpl"},{"key":"1845_CR135","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000917","volume":"5","author":"P Sharma","year":"2019","unstructured":"Sharma P, Sun Y, Neal J, Erley J, Shen J, Tischer S, Sonnenday CJ, Park JM (2019) Renal outcomes of liver transplantation recipients receiving standard immunosuppression and early renal sparing immunosuppression: a retrospective single center study. Transplant Direct 5:e480","journal-title":"Transplant Direct"},{"key":"1845_CR136","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/lt.25400","volume":"25","author":"U Cillo","year":"2019","unstructured":"Cillo U, Saracino L, Vitale A et al (2019) Very early introduction of everolimus in de novo liver transplantation: results of a multicenter, prospective, randomized trial. Liver Transpl 25:242\u2013251","journal-title":"Liver Transpl"},{"key":"1845_CR137","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001159","volume":"7","author":"Z Kadry","year":"2021","unstructured":"Kadry Z, Stine JG, Dohi T et al (2021) Renal protective effect of everolimus in liver transplantation: a prospective randomized open-label trial. Transplant Direct 7:e709","journal-title":"Transplant Direct"},{"key":"1845_CR138","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.trre.2015.09.001","volume":"30","author":"O Witzke","year":"2016","unstructured":"Witzke O, Sommerer C, Arns W (2016) Everolimus immunosuppression in kidney transplantation: What is the optimal strategy? Transplant Rev (Orlando) 30:3\u201312","journal-title":"Transplant Rev (Orlando)"},{"key":"1845_CR139","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1499-3872(15)60419-2","volume":"14","author":"C-Y Tang","year":"2015","unstructured":"Tang C-Y, Shen A, Wei X-F, Li Q-D, Liu R, Deng H-J, Wu Y-Z, Wu Z-J (2015) Everolimus in de novo liver transplant recipients: a systematic review. Hepatobiliary Pancreat Dis Int 14:461\u2013469","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"1845_CR140","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13179","volume":"49","author":"T-W Guan","year":"2019","unstructured":"Guan T-W, Lin Y-J, Ou M-Y, Chen K-B (2019) Efficacy and safety of everolimus treatment on liver transplant recipients: a meta-analysis. Eur J Clin Invest 49:e13179","journal-title":"Eur J Clin Invest"},{"key":"1845_CR141","doi-asserted-by":"publisher","first-page":"87","DOI":"10.21037\/tgh.2017.10.01","volume":"2","author":"D Ghinolfi","year":"2017","unstructured":"Ghinolfi D, Rreka E, Pezzati D, Filipponi F, De Simone P (2017) Perfusion machines and hepatocellular carcinoma: a good match between a marginal organ and an advanced disease? Transl Gastroenterol Hepatol 2:87","journal-title":"Transl Gastroenterol Hepatol"},{"key":"1845_CR142","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s13304-022-01321-6","volume":"74","author":"D Patrono","year":"2022","unstructured":"Patrono D, Romagnoli R (2022) Plead for a paradigm shift in machine perfusion indications in liver transplantation. Updates Surg 74:1485\u20131487","journal-title":"Updates Surg"},{"key":"1845_CR143","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/lt.25833","volume":"26","author":"P Magistri","year":"2020","unstructured":"Magistri P, Olivieri T, Guidetti C, Guerrini GP, Agnoletti V, Muiesan P, Di Benedetto F (2020) Pushing the limits in donation after circulatory death donor selection: optimizing graft rehabilitation with ex vivo machine perfusion. Liver Transpl 26:1368\u20131372","journal-title":"Liver Transpl"},{"key":"1845_CR144","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1016\/j.transproceed.2019.06.008","volume":"51","author":"T Olivieri","year":"2019","unstructured":"Olivieri T, Magistri P, Guidetti C et al (2019) University of modena experience with liver grafts from donation after circulatory death: what really matters in organ selection? Transplant Proc 51:2967\u20132970","journal-title":"Transplant Proc"},{"key":"1845_CR145","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1097\/TP.0000000000003595","volume":"105","author":"R De Carlis","year":"2021","unstructured":"De Carlis R, Schlegel A, Frassoni S et al (2021) How to preserve liver grafts from circulatory death with long warm ischemia? A retrospective italian cohort study with normothermic regional perfusion and hypothermic oxygenated perfusion. Transplantation 105:2385\u20132396","journal-title":"Transplantation"},{"key":"1845_CR146","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s13304-020-00834-2","volume":"72","author":"D Patrono","year":"2020","unstructured":"Patrono D, Lupo F, Romagnoli R (2020) Shifting from donor to donor-recipient matching perspective in defining indications for machine perfusion in liver transplantation. Updates Surg 72:913\u2013915","journal-title":"Updates Surg"},{"key":"1845_CR147","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21165791","author":"Y Boteon","year":"2020","unstructured":"Boteon Y, Flores Carvalho MA, Panconesi R, Muiesan P, Schlegel A (2020) Preventing tumour recurrence after liver transplantation: the role of machine perfusion. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21165791","journal-title":"Int J Mol Sci"},{"key":"1845_CR148","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224890","volume":"14","author":"G Oldani","year":"2019","unstructured":"Oldani G, Peloso A, Slits F et al (2019) The impact of short-term machine perfusion on the risk of cancer recurrence after rat liver transplantation with donors after circulatory death. PLoS\u00a0One 14:e0224890","journal-title":"PLoS\u00a0One"},{"key":"1845_CR149","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/SLA.0000000000004258","volume":"272","author":"M Mueller","year":"2020","unstructured":"Mueller M, Kalisvaart M, O\u2019Rourke J et al (2020) Hypothermic oxygenated liver perfusion (HOPE) prevents tumor recurrence in liver transplantation from donation after circulatory death. Ann Surg 272:759\u2013765","journal-title":"Ann Surg"},{"key":"1845_CR150","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12943-019-1047-6","volume":"18","author":"C Lu","year":"2019","unstructured":"Lu C, Rong D, Zhang B, Zheng W, Wang X, Chen Z, Tang W (2019) Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol Cancer 18:130","journal-title":"Mol Cancer"},{"key":"1845_CR151","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1159\/000485396","volume":"44","author":"J Zheng","year":"2017","unstructured":"Zheng J, Cai J, Li H et al (2017) Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. Cell Physiol Biochem 44:967\u2013981","journal-title":"Cell Physiol Biochem"},{"key":"1845_CR152","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12935-021-02204-3","volume":"21","author":"W Wu","year":"2021","unstructured":"Wu W, Wang Q, Han D, Li J, Nie Y, Guo D, Yang L, Tao K, Zhang X, Dou K (2021) Prognostic value of preoperative inflammatory markers in patients with hepatocellular carcinoma who underwent curative resection. Cancer Cell Int 21:500","journal-title":"Cancer Cell Int"},{"key":"1845_CR153","doi-asserted-by":"publisher","first-page":"5763430","DOI":"10.1155\/2019\/5763430","volume":"2019","author":"J Li","year":"2019","unstructured":"Li J, Li C, Zhuang Q, Peng B, Zhu Y, Ye Q, Ming Y (2019) The evolving roles of macrophages in organ transplantation. J Immunol Res 2019:5763430","journal-title":"J Immunol Res"},{"key":"1845_CR154","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/TP.0000000000002532","volume":"103","author":"PS Tan","year":"2019","unstructured":"Tan PS, Muthiah MD, Koh T et al (2019) Asian liver transplant network clinical guidelines on immunosuppression in liver transplantation. Transplantation 103:470\u2013480","journal-title":"Transplantation"},{"key":"1845_CR155","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1172\/JCI74370","volume":"124","author":"MH Oberbarnscheidt","year":"2014","unstructured":"Oberbarnscheidt MH, Zeng Q, Li Q, Dai H, Williams AL, Shlomchik WD, Rothstein DM, Lakkis FG (2014) Non-self recognition by monocytes initiates allograft rejection. J Clin Investig 124:3579\u20133589","journal-title":"J Clin Investig"},{"key":"1845_CR156","doi-asserted-by":"publisher","first-page":"7810","DOI":"10.4049\/jimmunol.0902194","volume":"183","author":"D Zecher","year":"2009","unstructured":"Zecher D, van Rooijen N, Rothstein DM, Shlomchik WD, Lakkis FG (2009) An innate response to allogeneic nonself mediated by monocytes. J Immunol 183:7810\u20137816","journal-title":"J Immunol"},{"key":"1845_CR157","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1111\/j.1600-6143.2007.01997.x","volume":"7","author":"WH Kitchens","year":"2007","unstructured":"Kitchens WH, Chase CM, Uehara S, Cornell LD, Colvin RB, Russell PS, Madsen JC (2007) Macrophage depletion suppresses cardiac allograft vasculopathy in mice. Am J Transplant 7:2675\u20132682","journal-title":"Am J Transplant"},{"key":"1845_CR158","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/ajt.15620","volume":"20","author":"J Ochando","year":"2020","unstructured":"Ochando J, Fayad ZA, Madsen JC, Netea MG, Mulder WJM (2020) Trained immunity in organ transplantation. Am J Transplant 20:10\u201318","journal-title":"Am J Transplant"},{"key":"1845_CR159","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.immuni.2018.09.008","volume":"49","author":"MS Braza","year":"2018","unstructured":"Braza MS, van Leent MMT, Lameijer M et al (2018) Inhibiting inflammation with myeloid cell-specific nanobiologics promotes organ transplant acceptance. Immunity 49:819-828.e6","journal-title":"Immunity"},{"key":"1845_CR160","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cll.2018.10.004","volume":"39","author":"JK Horwitz","year":"2019","unstructured":"Horwitz JK, Chun NH, Heeger PS (2019) Complement and transplantation: from new mechanisms to potential biomarkers and novel treatment strategies. Clin Lab Med 39:31\u201343","journal-title":"Clin Lab Med"},{"key":"1845_CR161","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/JHC.S292010","volume":"8","author":"S G\u00fcl-Klein","year":"2021","unstructured":"G\u00fcl-Klein S, K\u00e4stner A, Haber PK et al (2021) Recurrence of hepatocellular carcinoma after liver transplantation is associated with episodes of acute rejections. J Hepatocell Carcinoma 8:133\u2013143","journal-title":"J Hepatocell Carcinoma"},{"key":"1845_CR162","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1111\/ajt.15811","volume":"20","author":"T d\u2019Izarny-Gargas","year":"2020","unstructured":"d\u2019Izarny-Gargas T, Durrbach A, Zaidan M (2020) Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review. Am J Transplant 20:2457\u20132465","journal-title":"Am J Transplant"},{"key":"1845_CR163","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","volume":"7","author":"N Abdel-Wahab","year":"2019","unstructured":"Abdel-Wahab N, Safa H, Abudayyeh A et al (2019) Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 7:106","journal-title":"J Immunother Cancer"},{"key":"1845_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100170","volume":"2","author":"E De Martin","year":"2020","unstructured":"De Martin E, Michot J-M, Rosmorduc O, Guettier C, Samuel D (2020) Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep 2:100170","journal-title":"JHEP Rep"},{"key":"1845_CR165","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1177\/2050640618774631","volume":"6","author":"S Munker","year":"2018","unstructured":"Munker S, De Toni EN (2018) Use of checkpoint inhibitors in liver transplant recipients. United Eur Gastroenterol J 6:970\u2013973","journal-title":"United Eur Gastroenterol J"},{"key":"1845_CR166","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1634\/theoncologist.2019-0659","volume":"25","author":"V Kumar","year":"2020","unstructured":"Kumar V, Shinagare AB, Rennke HG, Ghai S, Lorch JH, Ott PA, Rahma OE (2020) The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist 25:505\u2013514","journal-title":"Oncologist"},{"key":"1845_CR167","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/ajt.15617","volume":"20","author":"MF Nordness","year":"2020","unstructured":"Nordness MF, Hamel S, Godfrey CM, Shi C, Johnson DB, Goff LW, O\u2019Dell H, Perri RE, Alexopoulos SP (2020) Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? Am J Transplant 20:879\u2013883","journal-title":"Am J Transplant"},{"key":"1845_CR168","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2021.11","author":"C Yin","year":"2021","unstructured":"Yin C, Baba T, He AR, Smith C (2021) Immune checkpoint inhibitors in liver transplant recipients\u2014a review of current literature. Hepatoma Res. https:\/\/doi.org\/10.20517\/2394-5079.2021.11","journal-title":"Hepatoma Res"},{"key":"1845_CR169","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1634\/theoncologist.2018-0195","volume":"24","author":"LE Aguirre","year":"2019","unstructured":"Aguirre LE, Guzman ME, Lopes G, Hurley J (2019) Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue. Oncologist 24:394\u2013401","journal-title":"Oncologist"},{"key":"1845_CR170","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1053\/j.gastro.2017.01.063","volume":"152","author":"EN De Toni","year":"2017","unstructured":"De Toni EN, Gerbes AL (2017) Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient. Gastroenterology 152:1631\u20131633","journal-title":"Gastroenterology"},{"key":"1845_CR171","doi-asserted-by":"publisher","unstructured":"Ernstoff MS, Puzanov I, Robert C, Diab A, Hersey P (eds) (2019) SITC\u2019s guide to managing immunotherapy toxicity. https:\/\/doi.org\/10.1891\/9780826172150","DOI":"10.1891\/9780826172150"},{"key":"1845_CR172","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","volume":"10","author":"K Esfahani","year":"2019","unstructured":"Esfahani K, Al-Aubodah T-A, Thebault P et al (2019) Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation. Nat Commun 10:4712","journal-title":"Nat Commun"},{"key":"1845_CR173","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/onco.13539","volume":"26","author":"I Tsung","year":"2021","unstructured":"Tsung I, Worden FP, Fontana RJ (2021) A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma. Oncologist 26:133\u2013138","journal-title":"Oncologist"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-024-01845-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-024-01845-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-024-01845-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T15:24:01Z","timestamp":1716823441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-024-01845-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":173,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1845"],"URL":"https:\/\/doi.org\/10.1007\/s13304-024-01845-z","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"13 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Cillo Umberto, Carraro Amedeo, Avolio W. Alfonso, Cescon Matteo, Di Benedetto Fabrizio, Giannelli Valerio, Magistri Paolo, Nicolini Daniele, Vivarelli Marco, Lanari Jacopo have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Standards, Research involving human participants and\/or animals, and Informed consent"}}]}}